Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7436 Phase III Study in Adolescents for Prevention of Chemotherapy-Induced Nausea and Vomiting
2018-000662-11Phase 3
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Ono Pharmaceutical. Primary endpoints: Efficacy endpoints, Safety endpoints and 1 more.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2018-000662-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000662-11.